Redeye states that Enea showed in Q2 that organic growth is here to stay, delivering +14% y/y growth...
Doro delivered better than expected Q2 report on all key metrics.
Cibus' Q2 2024 income from property management (IFPM) was 6% above Infront consensus, but the result...
Redeye raises its forecasts and Base Case following Hexatronic’s Q2 report, showing a solid sequenti...
- Higher sales and gross margin in Q2 - EBITDA revised up 2.
- Q2e: 21% ARR growth and adj. EBITDA of DKK 1.1m - '24e likely to be even more back-end loaded vs.
- Rec. PTP 7% below ABGSCe - CEPS est. +2.7-0.6% for '25-26e due to projects - Share trading at a ~3...
Redeye endorses today’s news that the ETA (“European Thyroid Association”) recommends Emcitate as a ...
Despite a softer period for Vitrolife’s typically reliable Consumables and APAC, the company deliver...
- 10% beat on EBITDA vs cons - Strong growth in Technology, but continued weakness in Genetics - Est...
Consti reports its Q2 results on Friday 19th of July.
Redeye comments on Doro´s second quarter of the year.
- Sales -2% vs. cons, adj. EBIT -19% vs. cons - Utilisation up due to reduction of unstaffed FTEs - ...
Redeye updates its estimates and valuation following Serstech's Q1 2024 report.
- Beat on Q2 sales (+3%) and EBITDA (+24%) vs ABGSCe - EBITDA up 2% for '24e and 1% for '25e - Our c...
- Rising freight rates dilute the gross margin - '24e-'26e EBITA down 5-1% - '24e-'25e lease adj.
- Q2e: sales +41% y-o-y (0% excl. SDR), ~9% EBIT margin - Lifting '24e EPS by 41% on a DKK 135m Q2e ...
Redeye updates its estimates for Ependion following the Q2 2024 report, which showed stronger sales ...
AlzeCure Pharma fortsätter alltjämt att generera data för sina projekt har bland annat presenterat n...
Redeye provides an initial comment on the Q2 2024 report from Serstech.
